Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
NOVATO, Calif., May 10, 2017 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 16, 2017 at 3:00 pm PT in Las Vegas, NV.
The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
